Literature DB >> 21400374

Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.

Edward L Korn1, Boris Freidlin.   

Abstract

If definitive evidence concerning treatment effectiveness becomes available from an ongoing randomized clinical trial, then the trial could be stopped early, with the public release of results benefiting current and future patients. However, stopping an ongoing trial based on accruing outcome data requires methodological rigor to preserve validity of the trial conclusions. This has led to the use of formal interim monitoring procedures, which include inefficacy monitoring that will stop a trial early when the experimental treatment appears not to be working. For participants, inefficacy monitoring is especially important as it ensures that they are not being treated worse than if they had not enrolled on the trial. We discuss the importance of reporting with trial results the formal interim inefficacy monitoring guidelines that were utilized, and, if none were used, the reasons for their absence. A survey of two leading medical journals suggests that this is not current practice.

Entities:  

Mesh:

Year:  2011        PMID: 21400374     DOI: 10.1080/15265161.2010.546471

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  2 in total

1.  Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2018-06-27       Impact factor: 44.544

2.  Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination.

Authors:  Rebecca J Williams; Tony Tse; Katelyn DiPiazza; Deborah A Zarin
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.